HWHG(SH:600079) Jing Ji Guan Cha Bao·2026-02-25 03:25Core Viewpoint - ST Renfu plans to raise between 3 billion to 3.5 billion RMB through a stock issuance to its controlling shareholder, aiming to fund various innovative drug research projects and enhance production capacity [1][2]. Group 1: Fundraising Details - The company intends to issue shares at a price of 14.95 RMB per share, with a minimum issuance of 200,668,897 shares and a maximum of 234,113,712 shares, not exceeding 30% of the total share capital prior to the issuance [1]. - The net proceeds from the fundraising will be allocated to projects including innovative drug R&D, a manufacturing base for complex formulations, and digital transformation initiatives [1][2]. Group 2: Strategic Goals - The fundraising will enable the company to enhance its innovative drug development capabilities, improve R&D efficiency, and accelerate clinical research and commercialization of new products [2]. - The company aims to systematically advance digital and intelligent upgrades across five key areas: corporate governance, smart manufacturing, R&D innovation, marketing systems, and talent organization, thereby improving operational efficiency and market responsiveness [2]. - The capital raised will strengthen the company's financial position, reduce asset-liability ratios, and optimize its financial structure, enhancing financial stability and risk resilience [2].